Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?

3. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637–1647 4. Jean G, Terrat JC, Vanel T et al. High levels of serum Fibroblast Growth Factors (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792– 2796 5. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584–592 6. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545–2552 7. Charra B, Terrat JC, Vanel T et al. Long thrice weekly hemodialysis: the Tassin experience. Int J Artif Organs 2004; 27: 265–283 8. Isakova T, Gutierrez O, Shah A et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19: 615–623 9. Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69: 531–537 10. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336–339 11. Krueger T, Westenfeld R, Ketteler M et al. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int 2009; 76: 18–22 12. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456–469